LAG3 and melanoma: Interestingly, Gal-3 binds lymphocyte-activation gene 3 (LAG3), the immune checkpoint of immune effector cells, and anti-LAG-3 (relatlimab) represents a novel FDA-approved inhibitor for combinational checkpoint therapy in melanoma [134].